Advertisement
ANIP vs PRPH
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIP is a Hold and PRPH is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANIP’s FA Score shows that 1 FA rating(s) are green whilePRPH’s FA Score has 1 green FA rating(s).
- ANIP’s FA Score: 1 green, 4 red.
- PRPH’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANIP’s TA Score shows that 4 TA indicator(s) are bullish while PRPH’s TA Score has 3 bullish TA indicator(s).
- ANIP’s TA Score: 4 bullish, 6 bearish.
- PRPH’s TA Score: 3 bullish, 5 bearish.
Price Growth
ANIP (@Pharmaceuticals: Generic) experienced а -7.86% price change this week, while PRPH (@Medical Specialties) price change was -12.84% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.42%. For the same industry, the average monthly price growth was -7.04%, and the average quarterly price growth was +26.76%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -2.75%. For the same industry, the average monthly price growth was -1.62%, and the average quarterly price growth was +29.45%.
Reported Earning Dates
ANIP is expected to report earnings on Feb 26, 2026.
PRPH is expected to report earnings on Apr 01, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-4.42% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Medical Specialties (-2.75% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ANIP | PRPH | ANIP / PRPH | |
| Capitalization | 1.81B | 9.7M | 18,619% |
| EBITDA | 89M | -25.03M | -356% |
| Gain YTD | 45.459 | -69.159 | -66% |
| P/E Ratio | 50.67 | N/A | - |
| Revenue | 747M | 5.59M | 13,368% |
| Total Cash | 224M | 171K | 130,994% |
| Total Debt | 622M | 7.87M | 7,907% |
ANIP | PRPH | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 64 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 31 | 100 | |
SMR RATING 1..100 | 88 | 99 | |
PRICE GROWTH RATING 1..100 | 52 | 93 | |
P/E GROWTH RATING 1..100 | 53 | 10 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PRPH's Valuation (79) in the Household Or Personal Care industry is in the same range as ANIP (94) in the Pharmaceuticals Other industry. This means that PRPH’s stock grew similarly to ANIP’s over the last 12 months.
ANIP's Profit vs Risk Rating (31) in the Pharmaceuticals Other industry is significantly better than the same rating for PRPH (100) in the Household Or Personal Care industry. This means that ANIP’s stock grew significantly faster than PRPH’s over the last 12 months.
ANIP's SMR Rating (88) in the Pharmaceuticals Other industry is in the same range as PRPH (99) in the Household Or Personal Care industry. This means that ANIP’s stock grew similarly to PRPH’s over the last 12 months.
ANIP's Price Growth Rating (52) in the Pharmaceuticals Other industry is somewhat better than the same rating for PRPH (93) in the Household Or Personal Care industry. This means that ANIP’s stock grew somewhat faster than PRPH’s over the last 12 months.
PRPH's P/E Growth Rating (10) in the Household Or Personal Care industry is somewhat better than the same rating for ANIP (53) in the Pharmaceuticals Other industry. This means that PRPH’s stock grew somewhat faster than ANIP’s over the last 12 months.
| ANIP | PRPH | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 87% | 1 day ago 79% |
| Stochastic ODDS (%) | 1 day ago 83% | 7 days ago 90% |
| Momentum ODDS (%) | 1 day ago 72% | 7 days ago 83% |
| MACD ODDS (%) | 1 day ago 75% | N/A |
| TrendWeek ODDS (%) | 1 day ago 67% | 1 day ago 83% |
| TrendMonth ODDS (%) | 1 day ago 69% | 1 day ago 84% |
| Advances ODDS (%) | 17 days ago 75% | N/A |
| Declines ODDS (%) | 1 day ago 69% | 1 day ago 85% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 75% |
| Aroon ODDS (%) | 1 day ago 77% | 1 day ago 85% |
Advertisement
ANIP and
Correlation & Price change
A.I.dvisor indicates that over the last year, ANIP has been loosely correlated with ORGO. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIP jumps, then ORGO could also see price increases.
| Ticker / NAME | Correlation To ANIP | 1D Price Change % | ||
|---|---|---|---|---|
| ANIP | 100% | -0.81% | ||
| ORGO - ANIP | 45% Loosely correlated | -6.88% | ||
| AMRX - ANIP | 33% Loosely correlated | -0.43% | ||
| SNDL - ANIP | 31% Poorly correlated | -3.57% | ||
| AKBA - ANIP | 29% Poorly correlated | -3.64% | ||
| PRPH - ANIP | 29% Poorly correlated | -9.53% | ||
More | ||||
PRPH and
Correlation & Price change
A.I.dvisor tells us that PRPH and ANIP have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PRPH and ANIP's prices will move in lockstep.
| Ticker / NAME | Correlation To PRPH | 1D Price Change % | ||
|---|---|---|---|---|
| PRPH | 100% | -9.53% | ||
| ANIP - PRPH | 28% Poorly correlated | -0.81% | ||
| ICCM - PRPH | 27% Poorly correlated | -3.21% | ||
| NVST - PRPH | 27% Poorly correlated | -0.94% | ||
| ISPC - PRPH | 24% Poorly correlated | -8.52% | ||
| MTD - PRPH | 24% Poorly correlated | +0.57% | ||
More | ||||